I

Intellia Therapeutics

CRISPR-Cas9 genome-editing therapeutics developer

Director Alternative Site of Care Strategy Lead

Business Development & PartnershipsConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • A bachelor's degree is required; an advanced degree such as an MBA, MHA, or related degree is preferred.
  • At least 10 years of experience in biotech or pharmaceutical commercial roles, with direct experience in specialty pharmacy, infusion services, site-of-care strategy, trade or distribution, or strategic account management.
  • Demonstrated experience building or scaling a new channel, program, or network from the ground up, ideally involving external provider contracting or negotiation.
  • Direct experience working with alternative sites of care or independent infusion providers is required.
  • Proven ability to lead complex, matrixed, cross-functional initiatives without direct authority over contributing teams.
  • Strong contracting and negotiation acumen, including comfort partnering closely with Legal and Market Access on deal terms.
  • Willingness to travel extensively, estimated at 40–60%, to engage independent infusion providers nationally.

Responsibilities

  • Serve as the single owner and strategic lead for the alternative site-of-care channel, defining criteria, sequencing, and the roadmap for prioritizing and onboarding independent infusion providers.
  • Develop the business case, resourcing plan, and success metrics for alternative site-of-care integration in partnership with the VP of Sales and Strategic Accounts leadership.
  • Track and report progress against the operationalization plan, including timing, budget, and risk to the target go-live window.
  • Lead direct outreach, relationship-building, and negotiation with independent infusion providers to bring them into the Lonvo-z ATC network as alternative sites of care.
  • Partner with Legal and Market Access to negotiate and finalize contracting terms with selected partners.
  • Serve as the primary relationship owner for onboarded accounts after contracting, ensuring a smooth transition into active network status.
  • Coordinate internal workstreams to ensure execution is timely and integrated.
  • Align with Sales Account Leads, Patient Access Leads, and Nurse Case Managers to build the capacity and playbooks needed to support alternative sites of care alongside existing ATCs.
  • Direct development of alternative-site-specific marketing assets and adaptation of existing ATC materials for that channel.
  • Partner on Travel & Lodging modeling, Hub workflow integration, and development of forms and processes for the new alternative-site patient pathway.
  • Support Medical Affairs on Lonvo-z clinical data discussions, protocol development, and hereditary angioedema education and training relevant to providers, including attack versus anaphylaxis recognition and treatment response.
  • Partner on gross-to-net, average selling price modeling, and fair market value assessment specific to the alternative-site channel.
  • Ensure alternative-site accounts are built out in the customer relationship management system and properly incorporated into forecasting as a distinct source of business.
  • Coordinate data integrations, such as status reporting, into the CDE to support alternative-site visibility and reporting.
  • Provide regular updates to the VP of Sales and relevant governance bodies on progress, budget, and risks.
  • Support preparation of the full financial impact assessment and business case for formal approval.

Desired Qualifications

  • Experience in rare disease and/or launch-stage commercial environments is preferred.
  • Familiarity with hereditary angioedema or gene-editing therapies is a plus.

About the Company

Intellia Therapeutics

CRISPR-Cas9 genome-editing therapeutics developer

Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.

Company size
501-1,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Intellia Therapeutics

See more jobs